Oxalomalate suppresses metastatic melanoma through IDH-targeted stress response to ROS

References

• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med. 2012;10:23.
   PubMed Web of Science ®Google Scholar
• Kanzler MH, Swetter SM. Malignant melanoma. J Am Acad Dermatol. 2003;48:780–783.
   PubMed Web of Science ®Google Scholar
• Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127:679–695.
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. JCO. 2009;27:6199–6206.
   PubMed Web of Science ®Google Scholar
• Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5–24.
   PubMed Web of Science ®Google Scholar
• Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3:362–374.
   PubMed Web of Science ®Google Scholar
• Palecek SP, Loftus JC, Ginsberg MH, et al. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature. 1997;385:537–540.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhao Z, Meng X, et al. Migration and invasion in B16-F10 mouse melanoma cells are regulated by Nrf2 inhibition during treatment with ionizing radiation. Oncol Lett. 2018;16:1959–1966.
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG, Liotta LA, Kleiner DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434–1441.
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.
   PubMed Web of Science ®Google Scholar
• Nikkola J, Vihinen P, Vuoristo MS, et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005;11:5158–5166.
   PubMed Web of Science ®Google Scholar
• van den Oord JJ, Paemen L, Opdenakker G, et al. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol. 1997;151:665–670.
   PubMed Web of Science ®Google Scholar
• Ingebretsen OC. Mechanism of the inhibitory effect of glyoxylate plus oxaloacetate and oxalomalate on the NADP-specific isocitrate dehydrogenase. Biochim Biophys Acta. 1976;452:302–309.
   PubMedGoogle Scholar
• Yang JH, Park JW. Oxalomalate, a competitive inhibitor of NADP+-dependent isocitrate dehydrogenase, enhances lipid peroxidation-mediated oxidative damage in U937 cells. Arch Biochem Biophys. 2003;416:31–37.
   PubMed Web of Science ®Google Scholar
• Kwon SJ, Park JW, Choi WK, et al. Inhibition of metal-catalyzed oxidation systems by a yeast protector protein in the presence of thioredoxin. Biochem Biophys Res Commun. 1994;201:8–15.
   PubMed Web of Science ®Google Scholar
• Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012;24:981–990.
   PubMed Web of Science ®Google Scholar
• Foyer CH, Ruban AV, Noctor G. Viewing oxidative stress through the lens of oxidative signalling rather than damage. Biochem J. 2017;474:877–883.
   PubMed Web of Science ®Google Scholar
• Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science. 2010;330:517–521.
   PubMed Web of Science ®Google Scholar
• Tobiume K, Matsuzawa A, Takahashi T, et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001;2:222–228.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Park JW. Oxalomalate, a competitive inhibitor of NADP+-dependent isocitrate dehydrogenase, regulates heat shock-induced apoptosis. Biochem Biophys Res Commun. 2005;337:685–691.
   PubMed Web of Science ®Google Scholar
• Izuta H, Chikaraishi Y, Shimazawa M, et al. 10-Hydroxy-2-decenoic acid, a major fatty acid from royal jelly, inhibits VEGF-induced angiogenesis in human umbilical vein endothelial cells. Evid Based Complement Altern Med. 2009;6:489–494.
   PubMed Web of Science ®Google Scholar
• Machado D, Shishido SM, Queiroz KCS, et al. Irradiated riboflavin diminishes the aggressiveness of melanoma in vitro and in vivo. Plos One. 2013;8:e54269.
   PubMed Web of Science ®Google Scholar
• Jo S-H, Son M-K, Koh H-J, et al. Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem. 2001;276:16168–16176.
   PubMed Web of Science ®Google Scholar
• Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005;11:7003–7011.
   PubMed Web of Science ®Google Scholar
• Maeda M, Suga T, Takasuka N, et al. Effect of bis(bilato)-1,2-cyclohexanediammineplatinum(II) complexes on lung metastasis of B16-F10 melanoma cells in mice. Cancer Lett. 1990;55:143–147.
   PubMed Web of Science ®Google Scholar
• Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006;20:2149–2182.
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst. 1976;57:1199–1202.
   PubMed Web of Science ®Google Scholar
• Gupta PB, Kuperwasser C, Brunet J-P, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005;37:1047–1054.
   PubMed Web of Science ®Google Scholar
• Wells A, Grahovac J, Wheeler S, et al. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 2013;34:283–289.
   PubMed Web of Science ®Google Scholar
• Pencheva N, Buss CG, Posada J, et al. Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell. 2014;156:986–1001.
   PubMed Web of Science ®Google Scholar
• Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–333.
   PubMed Web of Science ®Google Scholar
• Lopez JI, Camenisch TD, Stevens MV, et al. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res. 2005;65:6755–6763.
   PubMed Web of Science ®Google Scholar
• Rajoria S, Suriano R, Wilson YL, et al. 3,3′-Diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncol Rep. 2011;25:491–497.
   PubMed Web of Science ®Google Scholar
• Justus CR, Leffler N, Ruiz-Echevarria M, et al. In vitro cell migration and invasion assays. J Vis Exp. 2014;88:51046.
   Google Scholar
• Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011;11:512–522.
   PubMed Web of Science ®Google Scholar
• Wolf K, Wu YI, Liu Y, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 2007;9:893–904.
   PubMed Web of Science ®Google Scholar
• Lu P, Takai K, Weaver VM, et al. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011;3:a005058.
   PubMed Web of Science ®Google Scholar
• Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123–2133.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–174.
   PubMed Web of Science ®Google Scholar
• Toth M, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9 by Gelatin Zymography. Methods Mol Med. 2001;57:163–174.
   PubMedGoogle Scholar
• Crowe DL, Brown TN. Transcriptional inhibition of matrix metalloproteinase 9 (MMP-9) activity by a c-fos/estrogen receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion. Neoplasia. 1999;1:368–372.
   PubMedGoogle Scholar
• Dahl KC, Zeineldin R, Hudson L. PEA3 transcriptionally activates both MMP-9 and MMP-14 in response to EGF signaling in ovarian tumor cells. Cancer Res. 2007;67:3074–3084.
   PubMedGoogle Scholar
• Gum R, Lengyel E, Juarez J, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271:10672–10680.
   PubMed Web of Science ®Google Scholar
• Goldberg AL. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol. 2012;199:583–588.
   PubMed Web of Science ®Google Scholar
• Makowski L, Hayes DN. Role of LKB1 in lung cancer development. Br J Cancer. 2008;99:683–688.
   PubMed Web of Science ®Google Scholar
• Upadhyay S, Liu C, Chatterjee A, et al. LKB1/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer. Cancer Res. 2006;66:7870–7879.
   PubMed Web of Science ®Google Scholar
• Herrmann JL, Byekova Y, Elmets CA, et al. Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett. 2011;306:1–9.
   PubMed Web of Science ®Google Scholar
• Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448:807–810.
   PubMed Web of Science ®Google Scholar
• Co NN, Iglesias D, Celestino J, et al. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. Cancer. 2014;120:3457–3468.
   PubMed Web of Science ®Google Scholar
• Macip S, Igarashi M, Berggren P, et al. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol. 2003;23:8576–8585.
   PubMed Web of Science ®Google Scholar
• Liu B, Chen Y, St Clair D. ROS and p53: a versatile partnership. Free Radic Biol Med. 2008;44:1529–1535.
   PubMed Web of Science ®Google Scholar
• Caspari T. How to activate p53. Curr Biol. 2000;10:R315–R317.
   PubMed Web of Science ®Google Scholar
• Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004;23:2797–2808.
   PubMed Web of Science ®Google Scholar
• Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440–450.
   PubMed Web of Science ®Google Scholar
• Lee SM, Koh H-J, Park D-C, et al. Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002;32:1185–1196.
   PubMed Web of Science ®Google Scholar